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hematopoiesis and stem cells or
progenitor cells
Hematopoiesis is a delicately regulated process, which results
in the production of various blood cell types with functions
ranging widely from oxygen transport to immunity. The
maintenance of this system requires hematopoietic stem cells
(HSC) in the bone marrow that give rise to committed
progenitor cells, which in turn proliferate and differentiate into
functional end cells. Stem cells were initially discovered as cells
generating hematopoietic colonies in the spleen of lethally
irradiated mice, and hence the term ‘colony-forming units
(CFU)’ with the affix ‘S’ coined for ‘spleen’. Later, progenitor
cells producing CFU-S were found to be distinct from more
primitive bone marrow cells termed HSC. HSC are adult stem
cells, able to undergo self-renewal, or apoptosis, and to generate
progenitor cells for all hematopoietic lineages on demand. HSC
seem to maintain some stem-cell plasticity in vitro, implying
that under particular conditions they may differentiate into
nonhematopoietic cell lineages. Whether this mechanism is
important under physiological in vivo conditions is unclear. The
self-renewal capacity of HSC is associated with telomerase
activity, a reverse transcriptase preventing chromosomal
telomere shortening during cell division (which otherwise
would lead to genetic instability and replicative senescence). As
HSC divide, they first form common lymphoid and common
myeloid progenitors, which further diversify and differentiate
to B, T, or natural killer (NK) cells in the lymphoid lineage or
to granulocyte/monocyte, megakaryocyte, and erythrocyte
precursors within the myeloid lineage. Human HSC are
characterized by typical protein expression patterns. They are
notably CD34+ (CD34 is a cell adhesion molecule) and CD38.
CD34+ cells derived from peripheral blood, bone marrow, or
umbilical cord blood are able to provide long-term engraftment
of hematopoiesis in the bone marrow. Peripheral blood CD34+
HSC have become the most frequently used source of stem cells
in allogeneic or autologous stem-cell transplantation, providing
faster neutrophil and platelet recovery than bone marrow-
derived CD34+ HSC. Transplantation using stem cells derived
from umbilical cord blood is possibly effective, but still
experimental and limited by the modest cell doses available
from such harvests (see Figure 1).
Hematopoiesis also depends on the microenvironment
offered within the bone marrow cavities. HSC and their progeny
are embedded in a meshwork of nonhematopoietic cells, such
as fibroblasts, osteoblasts, and adipocytes, which in addition to
providing mechanical anchorage are also the source of factors
essential to sustain successful hematopoiesis. For example,
fibroblasts are an important source of granulocyte–macrophage
colony-stimulating factor (GM-CSF). Endothelial cells in the
marrow express CD34 which provides a homing signal to HSC
to remain there, and also antagonizes their maturation.
Disorders affecting nonhematopoietic cells may lead to failure
of hematopoiesis, as e.g. in osteomyelofibrosis, where marrow
cavities are obliterated by dense fibrous tissue, and
hematopoiesis is exiled to other organs such as the liver or the
spleen.
myeloid lineages
As a first step towards the myeloid lineage of hematopoietic cell
differentiation, HSC produce the common myeloid precursor
cell [producing cells of all myeloid lineages, hence labeled CFU-
GEMM (for CFU-granulocyte–erythrocyte–macrophage–
megakaryocyte)] which gains additional markers present on
CD34+ HSC. CD33 expressed on CFU-GEMM has become of
clinical interest, since anti-CD33 antibodies are now being
tested in clinical trials to treat acute myelogenous leukemia
(AML) expressing this protein. CFU-GEMM next move on to
feed the different myeloid lineages, i.e. erythroid, granulocyte/
monocyte, and megakaryocyte production lines, where cells
become increasingly specialized in their functions. These cellular
differentiation programs are largely maintained in clonal
neoplastic myeloproliferative disorders [e.g. chronic
myelogenous leukemia (CML)], but AML typically show
deficient maturation, and hence AML blasts are arrested early
in the myeloid production line.
Erythropoiesis shows two classes of progenitors. Burst-
forming units (erythroid) (BFU-E) are the earliest progenitors
committed exclusively to erythroid differentiation, and they give
rise to multi-clustered colonies of hemoglobin-producing cells.
The second more differentiated class consists of colony-forming
units (erythroid) (CFU-E). Erythropoietin is a compulsory
growth factor for erythroid development at the BFU-E and
CFU-E level, but it does not play a role in determining lineage
commitment of HSC. As myeloid progenitor cells move into the
granulocyte/monocyte lineage, they acquire characteristic
markers such as myeloperoxidase or CD38 which is expressed
on myeloblasts, but they lose ‘early’ markers such as CD33
which is not present beyond the myelocyte stage. A number of
‘late’ markers such as CD11b or leukocyte alkaline phosphatase
are still present on mature granulocytes. Interestingly,
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granulocytes in CML that are part of the malignant neoplastic
clone are leukocyte alkaline phosphatase negative. Granulocytic
precursors acquire typical granules. Primary granules are
present as of the promyelocytic stage [hence, acute
promyelocytic leukemia (APL) blasts are often heavily
granulated], and secondary granules are acquired at the
transition to the myelocyte stage. They contain proteins that
are only seen in cells of granulocytic lineage, and are
important for their proper functioning in host defense. AML
are clonally derived from transformed stem cells with the
capacity to differentiate up to an early point in myelopoiesis.
For example, blasts in APL reach the promyelocytic stage, but
do not differentiate beyond (maturation arrest).
Monocyte ontogeny follows the same principles as explained
for the granulocytic lineage. Monocytes may in turn serve as
precursors for dendritic cells, which are professional antigen-
presenting cells (APC) (see later). Unique cell-surface
markers indicating monocytic differentiation have been
difficult to identify. CD11b is also present on cells of
the monocytic lineage, if not specific, but CD14, a
lipopolysaccharide receptor, is major functional surface
protein on monocytes.
Megakaryopoiesis and ultimately platelet formation follow
the same principles. Progenitor cells committed to the
megakaryocyte lineage differentiate into promegakaryoblasts,
which in turn form mature megakaryocytes. These latter cells,
very conspicuous in bone marrow smears are unable to undergo
further cell division, but retain the capacity for DNA synthesis
and thus become polyploid. Platelets are shed from
megakaryocytes as ‘blebs’ formed of their cytoplasm.
Thrombopoietin is a chief stimulatory player in thrombopoiesis,
operating at all levels from progenitor cells to mature
megakaryocytes.
The identification of soluble factors responsible for the
extrinsic regulation of hematopoiesis had to await the era of
molecular biology to identify them as cytokines modulating
proliferation, differentiation, and the function of hematopoietic
cells. The cytokine family chiefly includes the CSF, which
stimulate CFU activity of hematopoietic progenitor cells.
Examples of CSF are erythropoietin or granulocyte colony-
stimulating factor (G-CSF). Erythropoietin is a typical hormone
produced in the kidney and released into the circulation to reach
its target cells in the bone marrow, particularly in response to
hypoxia. G-CSF induces the proliferation of granulocytic
progenitors and their differentiation to mature granulocytes and
it increases the functional activity of mature neutrophils (such
as chemotaxis, phagocytosis, and the like). Recombinant G-CSF
is clinically used to mobilize peripheral blood stem cells, which
it achieves by stimulating matrix metalloproteinase release from
degranulated neutrophils. These enzymes cleave adhesion
molecules expressed in bone marrow stromal cells, which in
turn causes the release of CD34+ stem cells into the circulation.
G-CSF mobilization of stem cells keeps them in the G0/G1 phase
of the cell cycle. Recombinant GM-CSF is no longer used in
the clinic, except in experimental immunotherapy protocols
with the aim to recruit dendritic APC.
The intrinsic regulation of hematopoiesis was overshadowed
in the literature by the excitement about the cloning of growth
factor genes. The role of hematopoietic transcription factors
was, however, increasingly gleaned from the study of the
molecular pathology of human acute leukemias. Many
chromosomal translocations in acute leukemias affect
transcription factors and profoundly alter their expression,
leading to aberrant cellular differentiation or apoptosis
programs. The term ‘co-stimulatory cytokines’ is sometimes
used for such molecules, which show little or no direct effect on
colony formation, but have the capacity to act synergistically
with CSF. Co-stimulatory cytokines include stem-cell factor
(SCF or c-kit ligand) or the FLT3 tyrosine kinase. SCF is
a transcription factor, which reacts with the c-kit receptor
present on CD34+CD38 bone marrow cells. It accelerates their
entry into the cell cycle, and in cooperation with BCL-2 prevents
apoptosis. SCF influences the differentiation to all
hematopoietic lineages. It may collaborate with almost every
known hematopoietic cytokine to promote colony formation.
Involvement of SCF in chromosomal translocations leads to its
inappropriate expression and thus contributes to
leukemogenesis, particularly in T-cell acute lymphoblastic
leukemia (ALL). Aberrant expression of FLT3 (often caused by
internal tandem duplications within the gene) is the single most
common gene abnormality in AML, and associated with an
aggressive clinical course. In contrast to such ‘general
practitioners’ in hematopoiesis, master regulators of
hematopoietic lineage commitment are specialized to
a particular lineage. For example, the CCAAT enhancer-binding
protein alpha (C/EBP alpha) is essential for normal neutrophil
granulocyte formation. Mutations inactivating the C/EBP alpha
gene lead to an AML subtype with a relatively good prognosis.
The molecular diagnosis of FLT3 and C/EBP alpha gene
mutations has provided important prognostic factors of clinical
relevance in AML, particularly within the heterogeneous group
of AML with a normal karyotype.
Figure 1. Hierarchical model of haematopoiesis. Pluripotent
haematopoietic stem cells (PHSC) feed into various haematopoietic
lineages whilst retaining the capacity for self-renewal. Lineage-committed
stem cells produce progeny destined to differentiate into red cells,
granulocytes, lymphoid cells, platelets etc. Proliferation and differentiation
in the bone marrow are directed by a concerted action of growth factors
(SCF, GM-CSF or G-CSF) and transcription factors which are particularly
important for cellular differentiation (i.e., myeloid: PU1, C/EBP(a);
lymphoid: E2A).
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the immune system and
lymphoid lineages
The human immune system is assigned the seemingly
impossible task to keep at bay pathogens seeking to invade the
organism, to clear away dead cells and tissues, to tell the
organism’s own cells from foreign cells (such as those
introduced through organ transplantation), and to assist in
wound healing. Conceptually, it may be divided into the
innate system and the adaptive system.
The innate immune system encompasses granulocytes,
monocytes, NK cells, and related cells as effector cells, which
typically act with a very short response time of within hours to
a few days. Pathogen recognition receptors (PRP) capable of
binding to specific pathogen-associated molecular patterns
(PAMP) may be present on their surface or as soluble proteins
in the circulation. The C-reactive proteins, often used in the
clinic as markers for the presence and activity of infection, are an
example. Typically cells operating in the innate system are
released as fully mature and functional cells from the bone
marrow. Consequences of PRP–PAMP interaction are the
phagocytosis of microorganisms, and synthesis as well as release
of interferons (IFNs), interleukins (ILs), chemokines, and
hematopoietic growth factors, many of which serve to amplify
the defense mechanisms against any aliens seeking to invade
the host.
The adaptive immune system deals primarily with the
generation of T-cell receptor (TCR) and B-cell receptor [i.e.
immunoglobulin (Ig)] diversity. It thus achieves two goals,
which are not met by the innate system: (i) the generation of an
incredibly diverse receptor repertoire and (ii) the amplification
of pathogen-specific cells as a reaction to the organism’s
exposure to pathogen. Innate immune function entirely
depends on molecules encoded by genes in germline
configuration, whereas the biological diversity of the adaptive
system and its specific immune responses are basedon the
creation of genetic diversity through physiological antigen
receptor gene rearrangements and somatic mutations, which
profoundly change the structures of germline TCR and Ig genes.
The cells contributing to adaptive immunity are the lymphoid
cells, with their production line determined very early in the
hematopoietic differentiation process, where the common
myeloid precursor splits from the common lymphoid
precursor cell.
B cells
B cells are the subset of lymphocytes specialized to synthesize
and release Ig. They are generated in the bone marrow, the
primary B-cell production site, from common lymphoid
progenitor cells which are CD34+, but lineage negative (lin),
implying that they lack expression of determinants present on
mature myeloid and mature lymphoid cells. Immature B cells
next move to the spleen where they differentiate into mature but
still naive B cells in a process referred to as secondary B-cell
development. The marginal zone corresponds to the outer limit
of the splenic white pulp and plays a critical role in the immune
response to T-cell-independent antigens. The maturation of
mature naive B cells depends on their positive selection by
antigen, or else they will die by neglect. Mature naive B cells next
migrate to lymph nodes where they undergo further
differentiation to become highly specialized effector plasma cells
producing specific antibody (Ab) in response to antigenic
challenge. In the secondary lymphoid organs, and upon
antigenic stimulation, they proliferate and differentiate further.
Nonresponsive B cells accumulate in the mantle zone of follicles,
surrounding the proliferating antigen-responsive B cells present
in a central germinal center of the follicles. Here they are
exposed to antigens presented by follicular dendritic cells rather
than in a soluble form, and develop via morphologically defined
stages of centroblasts or centrocytes to become either Ig-
secreting plasma cells or memory B cells. Malignant lymphoid
neoplasms mirror these various stages of lymphoid ontogeny
which is reflected by their morphology and their immunological
and molecular profiles. For example, follicular lymphoma and
diffuse large-B-cell lymphomas are derived from malignant
transformed B cells that show characteristics of germinal center
B cells, whereas the neoplastic cells in myeloma produce and
often secrete monoclonal Ig proteins, or at least parts thereof
(e.g. Ig light chains or Bence–Jones protein).
Critical checkpoints in this line of events are the transition
from pro-B cells to pre-B cells, still in the bone marrow, and the
move of transitional B cells to the spleen, at the point when they
start to express Ig light chains. The B-cell development pathway
is marked by the transient and stage-specific expression of
a number of cell-surface-associated molecules, which can be
detected by fluorescence-associated cell sorting (FACS) and
have become important in the classification of B-cell lymphoid
neoplasias. For example, early lymphoid precursors express
CD34+ and CD10, which in pro-B cells is complemented by the
B-cell markers CD19 and CD20. The physiological function
of CD20 is unknown, but nevertheless, CD20 has become
important in clinical oncology as the target of a monoclonal
antibody, rituximab, that has become established as
a complement to chemotherapy in a variety of B-cell
lymphomas and leukemias expressing this molecule. As B cells
become capable of expressing Ig heavy-chain genes of the l type,
CD34+ expression is lost, as is CD10 expression at the point
where B cells start to express surface Ig light chains and move to
the spleen. ALL can occur through neoplastic transformation of
early B-lymphoid cells in the bone marrow. Similar to AML,
ALL cells, e.g. B-cell precursor ALL blasts, are arrested at
a particular stage of B-lymphoid differentiation and retain the
respective marker profile.
B-cell-committed precursors and their downstream progeny
show rearrangement of Ig genes as a crucial feature of normal B-
cell development, since it forms the molecular basis to generate
antibody diversity. The earliest B-lineage-committed progenitor
is the pro-B cell where Ig heavy-chain gene rearrangement is
initiated. Ig heavy-chain genes are composed in the germline
configuration of a number of distinct separate sections termed
the variable (VH), diversity (DH), joining (JH), and constant
(C) regions. In a first step, a DH region is singled out and placed
next to a JH region, whereafter a VH region rearranges to the D–
JH complex (VHDJH joining). This process much depends on
enzymic machinery, where recombinases and recombinase-
activating genes act through the recognition of recombination
signal sequences located near the VH, JH, or D regions. Since
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such signal sequences also occur near oncogenes, e.g. the BCL-2
oncogene, recombinases may by mistake incorporate such alien
genes in the Ig gene recombination process, which provides
a molecular mechanism for the creation of chromosomal
translocations in B-cell neoplasias. If Ig heavy-chain gene
rearrangement is successful, cells firstly express the Ig heavy
chain of the mu-class, and are at this stage referred to as pre-B
cells. Rearrangement of Ig light chains is next in line, always
starting with kappa gene rearrangement and passing on to the
lambda gene, if kappa rearrangement fails. In parallel, heavy-
chain production may switch from mu-chains to gamma chains
present in immunoglobulin G. Once Ig light-chain
rearrangement has occurred, pre-B cells mature into B
lymphocytes that express the newly assembled Ig molecule on
their surface. Genetic diversity in the Ig gene repertoire can be
further enhanced through the introduction of extra nucleotides
(not encoded in the germline Ig gene) to DJH and VH–DJH
junctions by a nuclear enzyme termed terminal
deoxynucleotidyl transferase (TdT). TdT expression is regularly
assessed in FACS-generated marker profiles in lymphoid
neoplasias, and its presence is restricted to immature lymphoid
cancers, particularly B-cell ALL. Finally, somatic mutations can
occur in the V regions of a rearranged Ig gene, usually in
secondary lymphoid organs, and thus lead to even further
diversity and an increased affinity of the antibody to antigen.
Assessing the structure of antigen receptor genes has become an
important tool in molecular diagnostics of B-cell
lymphoproliferations. Since Ig gene rearrangement creates gene
sequences that are unique to a given B cell and its progeny, the
configuration of Ig genes has become an important marker of
clonality. In clonal neoplastic B-cell proliferations, all cells share
the very same Ig gene rearrangement, which can be detected
on molecular analysis, e.g. as a distinct single amplification
fragment produced by an Ig gene-specific PCR, whereas in
polyclonal lymphoid proliferations (seen in inflammatory
conditions) many different Ig gene fragments would be
amplified. Leukemia-specific Ig gene rearrangements can
specifically be detected by highly sensitive PCR and thus singled
out in clinical diagnostic material to trace minimal residual
leukemia after treatment, e.g. in ALL the presence or absence
of somatic mutations in the VH regions of rearranged Ig genes
has become important in the classification of B-cell chronic
lymphocytic leukemia (B-CLL), since B-CLL exhibiting somatic
VH mutations fare much better than B-CLL without this
molecular feature.
Specification towards a B-cell lineage is governed by a number
of genes, e.g. the transcription factors E2A and PAX5. Both
genes can be involved in chromosomal translocations, with their
aberrant expression contributing to the development of
malignant B-cell neoplasia. E2A is a partner gene in the
translocation t(1;19) seen in B-cell precursor ALL and in pre-
B-cell ALL, whereas PAX5 is involved in translocations found
in Ki+ B-cell lymphoma.
T cells
Similar principles as in B cells mostly apply to the maturation of
T cells, however, with a number of important differences. The
common lymphoid progenitor cells in the bone marrow send
out their progeny destined to form T cells to the thymus which
is critical for further development and final commitment to
the T-cell lineage. Within a day or so of their entry, thymic
lymphoid progenitors express CD25 (i.e. the IL-2 receptor).
Pro-T cells still maintain their TCR genes in the germline, but
TCR-beta-chain rearrangement begins with their move to
become pre-T cells. The molecular diagnosis of TCR gene
rearrangements can be used to assess clonality of T-cell
lymphoproliferations, which is often helpful, since there are no
easily detectable immunological surface markers available for
this particular purpose. The molecular machinery to achieve
TCR gene rearrangements in T cells is very similar to the one
used for Ig genes in B cells, and likewise, mistakes may lead to
chromosomal translocations. As in B-cell neoplasia, these
usually involve a TCR gene on one chromosome, and an
oncogene on the partner chromosome. Further along the T-cell
differentiation line, pre-T cells must undergo commitment to
become either CD4+ helper cells or the CD8+ cytotoxic T cells.
This step is usually prompted by the interaction of their TCR
protein with peptide/major histocompatibility complexes
(MHC). MHC class I molecules induce differentiation towards
CD8+ cytotoxic T cells, whereas MHC class II are associated
with CD4+ helper T-cell formation. The T-cell immune
response, part of the adaptive immune response system, is
hence triggered by contact with antigen peptide/MHC
complexes. Intracellular or endogenous antigens such as viral
proteins in the cytoplasm are broken down by proteosomes,
transported to the endocytoplasmic reticulum, and associated
with MHC class I molecules to be presented to the
immunocompetent cells. Extracellular or exogenous antigens
are taken up by specialized APC, dendritic cells, or
macrophages by endocytosis; broken down into peptides in
lysosomes; and associated with MHC class II molecules. After
contact with peptide/MHC class II complexes on APC, CD4+
helper T cells initiate specific immune responses by secreting
first of all soluble proteins such as IL-2 or IFN-c. These
cytokines provide the required assistance for the activation and
differentiation of other lymphoid cells (which are thus ‘helped’
to develop as required). CD4+ T cells also regulate immune
responses through direct cell–cell contact and not only via
secreted factors. If T cells expressing Fas, a member of the
tumor necrosis factor receptor family, meet other cells
expressing Fas ligand (FasL) on their surface, Fas+ T cells will
undergo apoptosis. Without such a mechanism of T-cell
elimination, the immune compartment would soon be
overpopulated. Unfortunately, some tumors also express FasL
which provides them with an escape mechanism from immune
surveillance by activated tumor-specific T cells. CD8+ cytotoxic
T cells (or cytotoxic T lymphocytes) may produce cytokines
upon contact with APC and kill the messenger that bears the
peptide/MHC class I complex for which they are specific.
Similar to the B-lymphoid system, T-cell neoplasms mirror
various stages of T-cell maturation, with T-cell ALL
corresponding to the early T-cell progenitor stage, and
peripheral T-cell lymphomas exhibiting markers of their more
mature postthymic normal counterparts. For example, mycosis
fungoides is a neoplasm clonally derived from transformed
CD4+ helper T cells.
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summary
In summary, our knowledge on the physiology of hematopoiesis
and the immune system has provided much specific
information of direct clinical relevance. The cloning of
hematopoietic growth factors or hormones has produced
compounds (such as erythropoietin or G-CSF) that help to
overcome side effects of chemotherapy, and provide convenient
techniques to harvest hematopoietic progenitor cells for
transplantation. The study of human leukemias has elucidated
the roles of genes important both in normal and leukaemic
hematopoiesis. Thus, molecular leukemia markers have become
available that are of unique clinical significance to assess
prognosis, to predict appropriate therapy, and to follow patients
after treatment detecting minimal residual disease. Finally, the
molecular unraveling of the unique molecular aberration in
CML has provided specific drugs, i.e. ABL tyrosine kinase
inhibitors, to induce a return of the marrow to assume normal
hematopoiesis. Along that way, molecularly targeted drugs to
overcome the differentiation block in acute leukemias are on the
horizon, to complement if perhaps not to replace cytotoxic
chemotherapy.
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